



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,044	08/17/2005	Amit Krishna Antarkar	21281/0208272-US0	2710
7278	7590	03/26/2010		
DARBY & DARBY P.C. P.O. BOX 770 Church Street Station New York, NY 10008-0770			EXAMINER YOUNG, MICAH PAUL	
			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			03/26/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/518,044

Applicant(s)

ANTARKAR ET AL.

Examiner

MICAH-PAUL YOUNG

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 December 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/C)
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date: _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____
- Paper No(s)/Mail Date: _____

DETAILED ACTION

Acknowledgment of Papers Received: Amendment/Response dated 12/09/09.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Lewis et al (WO 00/28989 hereafter '989) in view of Piper et al (WO 01/32158 hereafter '158) and Lui (EP 0 440 462 hereafter '462).

The '989 patent discloses a multilayered tablet comprising metformin and thiazolidinedione (abstract). The thiazolidinedione is pioglitazone present in concentrations from 15-45 mg (col. 4, lin. 5-30, ad page 5, lin. 5-8). The metformin is present in an amount of at least 500 mg (Examples). The layers are formed via conventional tableting with the non-biodegradable polymers are mixed with the metformin in a concentration above 35%, specifically 138% of the concentration of the metformin in the layer (page 3, lin. 20-22, Example

4). Metformin is present in a concentration 58% of the total dosage form (Example 4), where pioglitazone can be present in an amount of at least 10%, since 4mg of compound (I) corresponds to at least 10 mg of pioglitazone. The metformin layer comprises inert non-biodegradable includes methacrylic acid copolymers such as Eudragit L and RS powders, along with cellulose derivatives (col. 3, lin. 6-18). The tablet further comprises diluents, bulking agents such as lactose, and lubricants such as magnesium stearate (pg. 8, lin. 26-36). The tablets are formed using traditional tableting techniques (Examples). The polymer can also comprise a mixture of multiple polymers such Eudragit L, Eudragit RS and polyvinylpyrrolidone, present in a ratio of about 1:4.6:0.1 (Example 4).

Although the polymers and layers are granulated and present in powdered form, the reference is silent to the particle size of the granulations and active components. The preparation of small particles of antidiabetic active agents prepared with excipients is well known in the art as seen in the '158 patent. The '158 patent discloses a matrix tablet formulation comprising metformin in combination with glyburide (Examples). The matrix tablet is obtained by a process of forming granules of the metformin and blending the granules with tableting aids and compressing the resultant (pg. 25, lin. 15-25). The granules are sized mainly below 24 microns, including the tableting aids and metformin (pg. 5-15, lin. 25-35). It would have been obvious to include these particles into the formulation of the '989 patent since they both comprising similar carrier compounds.

Regarding the release of the preparation it is the position of the Examiner that such limitations do not overcome the prior art since these limitations are functional limitation falling directly from the compositional components. The granulations and resulting multilayered tablets

of the prior art comprising the same components combined in the same percentages, and as such would perform the same way under testing or in vivo. Applicant is reminded that a compound and its properties cannot be separated, as such the inherent properties of the composition of the instant claims would be found in the composition of the prior art since the compounds are the same.

Also the Office does not have the facilities for examining and comparing applicant's product with the product of the prior art in order to establish that the product of the prior art does not possess the same material structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is upon the applicant to prove that the claimed products are functionally different than those taught by the prior art and to establish patentable differences. *See Ex parte Phillips*, 28 U.S.P.Q.2d 1302, 1303 (PTO Bd. Pat. App. & Int. 1993), *Ex parte Gray*, 10 USPQ2d 1922, 1923 (PTO Bd. Pat. App. & Int.) and *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

The reference is also silent to the specific viscosity of the carrier excipients, however the viscosity of the components is an inherent feature of the compound, and the inclusion of specific compounds based on the specific viscosity is well known in the art as seen in the '462 patent. The '462 patent discloses a tablet formulation comprising a combination of hydroxypropyl celluloses ethers wherein the viscosities are either high or low (abstract). The high viscosities are above 3000 cps (pg. 3, lin. 5-35). The inclusion of these compounds helps to control the release of the active compounds (pg 2, lin. 55-58). It would have been obvious to include the high or low viscosity HPC ethers of the '462 in order to more precisely control the release of the active agents in the layers of the '989 patent.

With these things in mind it would have been obvious to combine the prior in order to more precisely control the release of the active agents in each layer. It would have been obvious to include the particles of the '158 patent into the formulation and method of the '989 patent since both patents disclose similar carrier formulation of microparticles of antidiabetic compounds. It would have been obvious to include the HPC ethers of the '462 patent in various viscosities in order to more precisely control the release of the active agents of the '989 patent. It would have been obvious to combine the prior art with an expected result of a stable multilayered tablet and a method of making such a tablet with activity to treat diabetes.

Response to Arguments

Applicant's arguments with respect to claims 1-20 have been considered but are moot in view of the new ground(s) of rejection. The '989 patent addresses the newly amended non-biodegradable polymer concentrations of claim 1. This new art requires further support of the '158 patent to address the particle size limitations. Both references were found on the Information Disclosure Statement dated 7/9/09. The '462 patent remains relevant to address the viscosity limitation of the HPMC.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH-PAUL YOUNG whose telephone number is (571)272-0608. The examiner can normally be reached on Monday-Friday 8:00-5:30; every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

/MICAH-PAUL YOUNG/
Examiner, Art Unit 1618